Lori J. Braender net worth and biography

Lori Braender Biography and Net Worth

Lori J. Braender joined the Company in September 2018. Prior to joining, Ms. Braender was an attorney at Day Pitney LLP for 35 years, most recently serving as a Partner and Chair of the firm’s Life Sciences Practice Group. Ms. Braender received a Bachelor of Science from Rider University and a J.D. from Seton Hall University School of Law.

What is Lori J. Braender's net worth?: The estimated net worth of Lori J. Braender is at least $1.72 million as of March 10th, 2026. Braender owns 442,879 shares of Aquestive Therapeutics stock worth more than $1,718,371 as of March 24th. This net worth estimate does not reflect any other investments that Braender may own. Additionally, Braender receives an annual salary of $713,220.00 as Insider at Aquestive Therapeutics. Learn More about Lori J. Braender's net worth.
How old is Lori J. Braender?: Braender is currently 68 years old. Learn More on Lori J. Braender's age.
What is Lori J. Braender's salary?: As the Insider of Aquestive Therapeutics, Inc., Braender earns $713,220.00 per year. The highest earning executive at Aquestive Therapeutics is Mr. Daniel Barber, CEO, President & Director, who commands a salary of $1,060,000.00 per year. Learn More on Lori J. Braender's salary.
How do I contact Lori J. Braender?: The corporate mailing address for Braender and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Lori J. Braender's contact information.
Has Lori J. Braender been buying or selling shares of Aquestive Therapeutics?: During the past quarter, Lori J. Braender has sold $167,225.34 of Aquestive Therapeutics stock. Most recently, Lori J. Braender sold 40,102 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a transaction totalling $167,225.34. Following the completion of the sale, the insider now directly owns 442,879 shares of the company's stock, valued at $1,846,805.43. Learn More on Lori J. Braender's trading history.
Who are Aquestive Therapeutics' active insiders?: Aquestive Therapeutics' insider roster includes Daniel Barber (CEO), Peter Boyd (Insider), Lori Braender (Insider), Melina Cioffi (SVP), Ernest Jr (CFO), Cassie Jung (COO), Sherry Korczynski (Insider), Carl Kraus (Insider), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.
Are insiders buying or selling shares of Aquestive Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 672,460 shares worth more than $3,342,230.34. The most recent insider tranaction occured on March, 10th when insider Peter E Boyd sold 29,814 shares worth more than $124,324.38. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.
Information on this page was last updated on 3/10/2026.

Lori J. Braender Insider Trading History at Aquestive Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2026	Sell	40,102	$4.17	$167,225.34	442,879
6/8/2022	Buy	13,761	$0.96	$13,210.56	38,761
3/16/2020	Buy	14,000	$1.54	$21,560.00	25,000

Lori J. Braender Buying and Selling Activity at Aquestive Therapeutics

Aquestive Therapeutics Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Today's Range

Now: $3.88

$3.77

$3.91

50 Day Range

MA: $3.83

$2.95

$4.37

2 Week Range

Now: $3.88

$2.12

$7.55

Volume

1,537,372 shs

Average Volume

5,024,399 shs

Market Capitalization

$473.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Lori Braender Biography and Net Worth

What is Lori J. Braender's net worth?

How old is Lori J. Braender?

What is Lori J. Braender's salary?

How do I contact Lori J. Braender?

Has Lori J. Braender been buying or selling shares of Aquestive Therapeutics?

Who are Aquestive Therapeutics' active insiders?

Are insiders buying or selling shares of Aquestive Therapeutics?